Debio 4126 clinical trial initiated to assess pharmacokinetics, safety in acromegaly and functioning GEP-NETs
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Abstract
Debio 4126's pharmacokinetics, pharmacodynamics, safety, and tolerability are being assessed in an open-label clinical trial (NCT06930625) recruiting participants with acromegaly or functioning GEP-NETs.